RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy ; volume:9 ; number:1 ; day:18 ; month:3 ; year:2019 ; pages:1-9 ; date:12.2019
Scientific reports ; 9, Heft 1 (18.3.2019), 1-9, 12.2019

Classification: Naturwissenschaften

Creator: Yoo, Byunghee
Jordan, Veronica Clavijo
Sheedy, Patrick
Billig, Ann-Marie
Ross, Alana
Pantazopoulos, Pamela
Medarova, Zdravka

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-019-41251-9

URN: urn:nbn:de:101:1-2019040701390931182068

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Yoo, Byunghee
Jordan, Veronica Clavijo
Sheedy, Patrick
Billig, Ann-Marie
Ross, Alana
Pantazopoulos, Pamela
Medarova, Zdravka
SpringerLink (Online service)

Other Objects (12)

PD-L1 degradation pathway and immunotherapy for cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

PD-L1 degradation pathway and immunotherapy for cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

PD-L1 degradation pathway and immunotherapy for cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

PD-L1 degradation pathway and immunotherapy for cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

PD-L1 degradation pathway and immunotherapy for cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

PD-L1 degradation pathway and immunotherapy for cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Related objects

Reset password